AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03909061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wheelchair Maintenance Training
Description: Wheelchair Maintenance Training Program: WMTP training consists of three parts. It starts with an overview of basic wheelchair maintenance items, continues with the second section discussing how to inspect the parts of a wheelchair and finishes with the third section discussing how to perform wheelchair maintenance on a wheelchair. Throughout the course, there are videos and pictures demonstrating the activities discussed in the training program. Participants will also be informed when a repair requires professional assistance and where such assistance may be found.
Study NCT01323530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate
Description: Intravenous (IV) bolus or infusion.
Study NCT01323530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral film-coated tablets.
Study NCT00742079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: Single, fixed 50-mg dose of D-cycloserine administered 1 hour prior to a CBT session
Study NCT00742079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: One-hour talk therapy session with a trained clinician aimed at increasing cognitive flexibility by examining alternative explanations to everyday situations
Study NCT01635608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: administration of 500 mg paracetamol
Study NCT01635608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talinolol
Description: administration of 50 mg talinolol
Study NCT01635608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: administration of 500 mg amoxicillin
Study NCT01635608 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-caloric water
Description: administration of 240 ml water
Study NCT01635608 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: caloric water
Description: administration of 240 ml caloric water (containing 25.5 g sucrose)
Study NCT04536246 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Quadriceps Tendon (BQT) arthroscopic-assisted ACL reconstruction
Description: New intervention method deployed in Indonesia to gain better clinical outcome for ACL--deficient patients requiring surgical treatment
Study NCT03867136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PZA sensitivity guided ultra-short all Oral Regimen
Description: Pyrazinamide 1500 mg daily; Levofloxacin ≤50kg 500 mg daily, >50kg 750mg daily; Linezolid: 600 mg daily; Cycloserine ≤50kg 500 mg daily, >50kg 750mg daily; Clofazimine 100 mg daily; All treatment is taken daily;
Study NCT03867136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Shorter Regimen
Description: Pyrazinamide 1500 mg daily;Levofloxacin 400 mg daily,; Prothionamide ≤50kg 500 mg daily, >50kg 750mg daily; Ethambutol: ≤50kg 750 mg daily, >50kg 1000mg daily; Clofazimine: 100 mg daily; Amikacin 600mg daily; High-dose isoniazid 600mg daily. All treatment is taken daily.
Study NCT02694783 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PyVST
Description: ex vivo generated polyomavirus-specific T cells from HLA-matched donor
Study NCT03524235 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Pre-Transplantation Total Body Irradiation
Study NCT03524235 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haploidentical Stem Cell Transplantation
Description: Haploidentical Stem Cell Transplantation
Study NCT03524235 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD56-Enriched Donor Lymphocyte Infusion
Description: CD56-Enriched Donor Lymphocyte Infusion
Study NCT03524235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Pre-Transplantation Bendamustine
Study NCT03524235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Pre-Transplantation Fludarabine
Study NCT03524235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Pre-Transplantation Rituximab (Rituximab for lymphoma diagnosis only)
Study NCT04300309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether:lumefantrine (2.5 mg:30 mg)
Description: Two oral dispersible tablets twice daily for three consecutive days. Each tablet contained artemether-lumefantrine 2.5 mg:30 mg.
Study NCT02346968 — intervention group
Intervention type: OTHER
Intervention: Blood and urine sampling
Description: Blood and urine sampling (in the context of routine sampling)
Study NCT00513461 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: immunoenzyme technique
Description: Correlative studies
Study NCT00513461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high performance liquid chromatography
Description: Correlative studies
Study NCT02314377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab dosing of 5mg/kg q 2 weeks for 12 weeks (2.5 mg/week).
Study NCT02015793 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection.
Study NCT05338502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally.
Study NCT00513461 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: high performance liquid chromatography
Description: Correlative studies
Study NCT03570996 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: Esophagectomy with minimally invasive approach of the chest including:~3 hole with R video-assisted thoracoscopic surgery (VATS), Ivor Lewis R VATS, Transhiatal
Study NCT05338502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: Administered orally.
Study NCT05338502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Administered orally.
Study NCT02526979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral
Study NCT03570996 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane catheter
Description: TAP group will have bilateral subcostal TAP catheters and single shot bilateral rectus sheath blocks placed at the end of the surgery, prior to emergence. Bilateral subcostal TAP catheters will be bolused with 20ml of .2% ropivacaine on each side and then infused with .2% ropivacaine at 10ml/ hr for 75 hours each. Rectus sheath blocks will be bilateral bolus 20ml of .2% ropivacaine
Study NCT03570996 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Description: Patients randomize the TEP group will have bilateral TEP placed at T8-9 +/- one level based on patient anatomy. TEP will be bolused with 5ml of 1.5% lidocaine with epinephrine and then started on infusion of .0625% bupivacaine plus 4 mcg/ml fentanyl plus 2 mcg/ ml epinephrine at 6ml/hr with a range of 6-12 ml/hr, titrating to optimize patient comfort. Epidurals are placed before surgery start time.
Study NCT04536246 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Single-Bundle Hamstring Tendon (SBHT) arthroscopic-assisted ACL reconstruction
Description: Comparator for New Reconstruction Technique
Study NCT03113292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: The protocol will be composed by the following exercises, structured in each session according to progression, difficulty and focus (respiration, stability, muscle strength and joint mobility): Arm Arcs, Bent Knee Opening, Sidelying, Dead Bug, Femur Arcs, Quadruped Series, Single Leg Stretch, Prone Press Up, Sidekick (Front to Back 1 e 2), Leg Pull Front, Mermaid, Spine Stretch, The Hundred, Pelvic Clock, Bridging, Stanging Roll Down, Swan, Saw, Dart, Swimming, Book Opening.~.
Study NCT03113292 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercises
Description: The protocol will be divided into 3 phases, each one composed by the following exercises and structured according to difficulty progression and focus (postural reeducation, muscle strength, balance, joint flexibility): Muscle strength exercises composed by abdominal exercises; back extension exercises; gluteus maximus exercises. Stretching exercises for the lower back, pelvis, iliopsoas muscle, tensor fascia latae muscle).
Study NCT03377023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenous nivolumab every 2 weeks.
Study NCT03377023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Intravenous nivolumab every 2 weeks.
Study NCT03377023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Intravenous ipilimumab every 6 weeks.
Study NCT03377023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Intravenous ipilimumab every 6 weeks.
Study NCT04067726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab is commercially available and will be provided at no cost to participants.
Study NCT04067726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be made available as 1 mL sterile, non-pyrogenic water solution in a single-use prefilled syringe.
Study NCT04067726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium
Description: -Participants will be instructed to take calcium (at least 500 mg) daily for 12 months between baseline examination and 12- month mammographic breast density examination.
Study NCT02015793 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for adalimumab
Description: Placebo for adalimumab pre-filled syringe, administered by subcutaneous injection to maintain double-blind.
Study NCT04659733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Anlotinib are divided into 3 dosage levels, including 8mg, 10mg, 12mg; Oral administration of anlotinib was given, qd, D1-D14; taken on an empty stomach, Every 3 weeks is a cycle, a total of 2 cycles; Starting from the first level of anlotinib, the dose will be ramped up in sequence.
Study NCT04067726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium
Description: -Participants will be instructed to take calcium (at least 500 mg) daily for 12 months between baseline examination and 12- month mammographic breast density examination.
Study NCT02832609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supine
Description: measurements after 30 minutes in complete supine position
Study NCT03377023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib 100-200 mg capsules by mouth twice daily for two-week cycles.
Study NCT03377023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nintedanib
Description: Nintedanib 100-200 mg capsules by mouth twice daily for two-week cycles.
Study NCT01837160 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac MRI scan
Description: Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.
Study NCT01837160 — intervention group
Intervention type: RADIATION
Intervention: CT-PET scan
Description: Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.
Study NCT01837160 — intervention group
Intervention type: PROCEDURE
Intervention: Echocardiogram
Description: Echocardiography.
Study NCT01837160 — intervention group
Intervention type: RADIATION
Intervention: CT-coronary angiogram scan
Description: CT-coronary angiogram following CT-PET scan. Standard protocol.
Study NCT01837160 — intervention group
Intervention type: PROCEDURE
Intervention: Aortic Valve Replacement
Description: For AVR (already scheduled prior to enrollment)
Study NCT02395861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuro-electrophysiologic analyses
Description: mismatch negativity (MMN) cognitive evoked potentials (CEP) auditory evoked potentials (AEP)
Study NCT01984697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)
Description: V503, a 9-valent HPV (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
Study NCT01984697 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)
Description: V503, a 9-valent HPV (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
Study NCT03070496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling will be performed at 6 months after myocardial infarction to analyse diagnostic and prognostic biomarkers
Study NCT03070496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECG
Description: ECG will be performed at 6 months after myocardial infarction
Study NCT03070496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI will be performed at 1month after myocardial infarction to analyse ventricular remodeling and reperfusion.
Study NCT03070496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire
Description: Patients will pass a quality of life questionnaire at 12 months after myocardial infarction
Study NCT03308825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine
Description: 0.25 mL, Intramuscular
Study NCT03308825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine
Description: 0.5 mL, Intramuscular
Study NCT03308825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High-Dose vaccine
Description: 0.5 mL, Intramuscular
Study NCT01878929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allergen(Tree, Grass, Weeds)
Description: Greer is manufacture of all allergen extract used in this study.
Study NCT03500055 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal Closure Bundle
Description: Surgeons will re-scrub, change gown and gloves prior to closure of fascia. Will also use new instruments, bovie tip, suction tip, and light handles, for closure of fascia, subcutaneous tissue, and skin
Study NCT02644590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Detailed in arm description
Study NCT03247790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally
Study NCT02347644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interview
Description: Motivational interviewing is a technique which aims to be both non-judgmental and non-confrontational. Its success depends largely on the presentation of objective feedback based on information provided by an individual. The technique involves acknowledgement that individuals who attend a counselling session, assessment or prevention program may be at different levels of readiness to change their alcohol consumption patterns, including:~* No perception of any alcohol consumption problem~* Realization of alcohol consumption problem with no corresponding action
Study NCT01094132 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Multispectral Digital Colposcope (MDC)
Description: The MDC has 2 components: an optical probe \& a multispectral colposcope. The optical wand makes use of fluorescence \& reflectance spectroscopy; a light is shone on the cervix and the wand reports what it sees to a computer. Since cancer \& healthy cells interact differently with light, a computer can detect abnormalities. The multispectral colposcope is based on a conventional colposcope, which is already widely used. However, it is also able to produce fluorescence \& polarized reflectance images of the entire cervix. Computer analysis of these images can detect abnormalities on the cervix, defining their location and shape.~This trial involves combined analysis of MDC data. This may lead to more effective diagnosis of cervical abnormalities. The MDC will be used with standard care for patients presenting with cervical abnormalities (as detected by a Pap test). The MDC will not be used to guide patient management decisions.~All study subjects will receive this same intervention.
Study NCT03544320 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activity Monitoring-Wrist worn wearable
Description: Participants wear an activity monitor on their wrist.
Study NCT03544320 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activity Monitoring-Waist-worn wearable
Description: Participants wear an activity monitor on their waist.
Study NCT04067726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Participants will be instructed to take vitamin D3 (at least 400 IU) supplements daily for 12 months between baseline examination and 12- month mammographic breast density examination.
Study NCT04067726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Participants will be instructed to take vitamin D3 (at least 400 IU) supplements daily for 12 months between baseline examination and 12- month mammographic breast density examination.
Study NCT02956642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Livongo Health System
Description: Participants will be asked to use the Livongo Health System to manage their blood glucose.
Study NCT02956642 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iHealth Glucose Meter
Description: Participants will be asked to use the iHealth Glucose Meter to take blood glucose measurements.
Study NCT02802163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Induction Phase: Panobinostat (dose escalation beginning at 10 mg) will be administered 3 times a week (TIW) by mouth every other week starting on day 1 of each cycle.~Maintenance Phase: Panobinostat will be administered TIW by mouth every other week starting on day 1 of each cycle. The dose of panobinostat during maintenance phase will be the same dose taken during cyce 8 of induction phase.
Study NCT02802163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Induction Phase: Carfilzomib will be administered at 20 mg/m\^2 on Cycle 1 Day 1. Beginning on Cycle 1 Day 2 the carfilzomib dose will be according to the assigned level of 27 mg/m\^2 or 36 mg/m\^2. Carfilzomib will be administered twice weekly IV on Days 1,2, 8,9,15, and 16.
Study NCT02802163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Induction Phase: Lenalidomide (25 mg) will be administered once-daily by mouth on Days 1-21, 25.~Maintenance Phase: Lenalidomide (10 mg) will be administered once-daily by mouth on days 1-21.
Study NCT02802163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Induction Phase: Dexamethasone (20 mg) will be administered twice weekly by mouth or by IV on Days 1,2, 8, 9, 15, and 16.
Study NCT06064084 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test
Description: Oral glucose tolerance test 50g
Study NCT06064084 — intervention group
Intervention type: OTHER
Intervention: Intravenous isoglycaemic glucose clamp
Description: Intravenous isoglycaemic glucose clamp
Study NCT06064084 — intervention group
Intervention type: OTHER
Intervention: Liquid Mixed meal test
Description: Liquid Mixed meal test 520 kcal
Study NCT03092323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at 200 mg intravenously every 3 weeks for patients on the treatment arm.
Study NCT03033654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen, Actinica
Description: Two Consecutive Sunscreen Applications
Study NCT00290862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Vertebral Augmentation of compression fractures
Description: Study eligible patients with painful osteoporotic compression fractures will be randomized to percutaneous vertebroplasty with CORTOSS (treatment group) or PMMA (active control group).
Study NCT00290862 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Vertebral Augmentation of compression fractures
Description: Study eligible patients with painful osteoporotic compression fractures will be randomized to percutaneous vertebroplasty with CORTOSS (treatment group) or PMMA (active control group).
Study NCT01855854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib: 250 mg is administered orally three times per day, until disease progression or untolerable toxicity.
Study NCT02481284 — intervention group
Intervention type: DEVICE
Intervention: Laser Doppler perfusion imaging
Description: LDPI is an extension of laser Doppler flowmetry (LDF) and was developed to generate a colour-coded perfusion image in a large area of skin.
Study NCT05983328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUYPS-1 one tablet
Description: After 7-day washout time, subjects will receive HUYPS-1 1 tablet.
Study NCT05983328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUYPS-1 nine tablets
Description: After 7-day washout time, subjects will receive HUYPS-1 9 tablets.
Study NCT04067726 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core needle biopsy
Description: Baseline and 12 months
Study NCT04067726 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Core needle biopsy
Description: Baseline and 12 months